Authors
Latest:
CAR T in Myeloma: Anito-cel Challenges and Evolving Treatment LinesCiara Freeman, MD, PhD, discusses the challenges of incorporating anito-cel into the treatment protocol for patients with multiple myeloma.
Latest:
Evolving Treatment Landscape: Integrating New Evidence Into Clinical PracticePanelists discuss how recent clinical trial data and emerging therapeutic options are reshaping the treatment paradigm for myelofibrosis, requiring thoughtful integration of new evidence into current clinical practice guidelines.
Latest:
Older Patients With Triple-Negative Breast Cancer Should Be Assessed Different for TreatmentEnrique Soto Pérez de Celis, MD, MSc, explains that although geriatric patients with breast cancer can be treated similarly to their younger counterparts, more steps are involved in the treatment decision-making process, starting with appropriate assessment of the patient.
Latest:
In Multiple Myeloma, Will ASCT Survive Collision With CAR T-Cell Therapy?With two recently approved chimeric antigen receptor T therapies targeting B-cell maturation antigen, this novel platform has altered the treatment paradigm for heavily-pretreated patients with multiple myeloma.
Latest:
Promising Results Seen With Pembrolizumab Plus Chemoradiation in Stage III NSCLCAntitumor activity was seen in the combination of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer, regardless of PD-L1 status or tumor histology.
Latest:
Combined Risk Factors Lead to Worse Outcomes in Colon CancerLuv N. Hajirawala, MD, discusses the findings from a retrospective analysis of the Surveillance, Epidemiology and End Results database looking at patients with stage III colon cancer.
Latest:
Unmet Needs in Oligometastatic Prostate CancerChad Tang, MD, discusses ongoing challenges for the treatment of patients with oligometastatic prostate cancer.
Latest:
Using Capecitabine/Temozolomide or 177Lu-Dotatate to Treat NETs Requires Real-World GuideA real-world guide to best practices in treating neuroendocrine tumors can improve patient outcomes.
Latest:
Second-Line Regorafenib/Nivolumab Is Deemed Safe for HCCFor patients with hepatocellular carcinoma treated in the second-line setting, the combination of regorafenib and nivolumab following 2 cycles of regorafenib monotherapy appeared safe, according to phase 1/2a study.
Latest:
Optimizing SCLC Management: The Role of Genomics and New TherapiesAriel Lopez-Chavez, MD, discusses the role of comprehensive genomic profiling in small cell lung cancer management.
Latest:
Liver Cancer Awareness Month: A Decade of Progress and Hope in Hepatocellular CarcinomaMahvish Muzaffar, MD, and Nasreen Vohra, MD, from the Brody School of Medicine/East Carolina University, discuss the past decade of progress in treatment for patients with hepatocellular carcinoma.
Latest:
Exploring Adjuvant Endocrine Therapy in the Breast Cancer SettingTerry P. Mamounas, MD, MPH, discusses the use of extended adjuvant therapy for patients with breast cancer and how the landscape is evolving.
Latest:
Behind the Development of Ivaltinostat in Metastatic PDACMohamad Adham Salkeni, MD, FRCPC, discusses the mechanism of action of ivaltinostat and what rationalizes its use in combination with capecitabine for patients with metastatic pancreatic adenocarcinoma.
Latest:
Future Directions for CAR T-Cell Therapies in Solid TumorsMichael Hurwitz, MD, PhD, discusses the advances being made for the treatment of chimeric antigen receptor T-cell therapies and next steps for evaluating the agent across solid tumors.
Latest:
Immune Checkpoint Inhibitors Offer New Approaches in Head and Neck CancerJoseph M. Curry, MD, discusses the introduction of immune checkpoint inhibitors for the treatment of patients with head and neck cancers.
Latest:
Atezolizumab/Bevacizumab Benefit Potentially Extends to Child-Pugh B HCCStacey Stein, MD, discusses the patient population and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma.
Latest:
Oncotype DX Used for Patients With Breast Cancer to Guide TherapyFengting Yan, MD, PhD, discusses how her clinical practice is informed by data and guidelines available on testing in breast cancer.
Latest:
Building a Patient-Centered Ecosystem Leads to Better CareWithin the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.
Latest:
Cervical Cancer Awareness Month: Trials Assess New ImmunotherapiesMargarett C. Ellison, MD, MHA, FACS, FACOG, gynecologic oncologist for Gynecologic Oncology of Tallahassee, a Division of Florida Cancer Specialists & Research Institute, reviews potential immunotherapy treatments for Cervical Cancer Awareness Month.
Latest:
Factors Correlating With Survival in Polycythemia VeraCarole Miller, MD, discusses notable factors which correlated with survival for patients with polycythemia vera in the REVEAL study.
Latest:
TAR-200 Offers New Hope for BCG-Unresponsive Bladder CancerJoseph Jacob, MD, discusses the promising impact of TAR-200.
Latest:
The Clinical Impact of Biased Language in HandoffsNegative language about patients can reduce clinician empathy and recall of critical health details, a recent study finds.
Latest:
Post–COVID-19 Infection Remains a Concern in Patients With CancerMany questions remain unanswered about COVID-19, and we are now experiencing another problem—postacute sequelae of SARS-CoV-2 infection, also referred to as post–COVID-19 condition or post-COVID syndrome.
Latest:
Miller Discusses Novel Targets in Endometrial CancerEirwen M. Miller, MD, discusses novel biomarkers that she believes will be important for endometrial cancer in the future.
Latest:
Next Steps in Study of PPAR-α Inhibitor Plus Nivolumab in RCCBruno R. Bastos, MD, discusses the future following a study assessing the changes among patients with renal cell carcinoma who were treated with nivolumab and TPST-1120.
Latest:
Future Perspectives on the Relapsed/Refractory Follicular Lymphoma Treatment LandscapeA panelist discusses how, despite recent advances in relapsed/refractory follicular lymphoma treatment, important unmet needs are being addressed through ongoing trials while reflecting on proud accomplishments in the field and expressing enthusiasm for developments in the coming year.
Latest:
Social Determinants of Health Impacting Oncology TodayIn season 4, episode 11 of Targeted Talks, Krisda Chaiyachati, MD, MPH, MSHP, discusses the social determinants of health for patients with cancer and key challenges for patients, like transportation insecurity.
Latest:
Recently Introduced Low-Intensity Options for Older Patients With AMLTapan Kadia, MD, discusses the recent and upcoming changes in treatment of acute myeloid leukemia for patients who are not candidates for intensive remission induction therapy.
Latest:
Patient Education, Shared Decision-Making, and Optimizing Care for ESR1-Mutated Breast CancerPanelists discuss how a multidisciplinary team approach to patient education and medication management is crucial for ensuring adherence and optimal outcomes with oral medications like elacestrant.
